IP Library › Granted Patent US 10,570,443
Granted Patent B2
US 10,570,443 · App. 15/516,014 · Granted Feb 25, 2020

Methods of quantifying cell-free DNA

Inventors: Ekkehard Schutz (Gottingen, DE); Julia Beck (Gottingen, DE)
Assignee: Chronix Biomedical
C12Q1/686
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,570,443
App. No.
15/516,014
Filed
Mar 30, 2017
Granted
Feb 25, 2020
Kind
B2
Art Unit
1637
USPC
435/6.12
Abstract

This invention provides a method of quantifying chimeric DNA in a cell-free DNA sample.

Claims (12)

1. A method of quantifying chimeric cfDNA in a sample from a patient, the method comprising:

(a) providing a cell-free DNA (cfDNA) sample from a blood, serum or plasma sample obtained from a patient;

(b) performing a multiplex digital PCR comprising at least a first amplification and a second amplification on the cfDNA sample to determine a correction factor to correct for the degree of fragmentation in the cfDNA sample to provide the fraction of cfDNA that can be amplified for an amplified product of a defined size, wherein the first amplification targets a first single copy genomic locus in the patient genome and results in production of a first amplicon; and a second amplification targets a second single copy genomic locus in the patient genome and results in production of a second amplicon, wherein the first and second amplicon differ in length by at least 50 base pairs;

(c) determining the proportion of the first or the second amplicon in the total amplified product from the digital PCR of step (b) to provide the correction factor for the fraction of the cfDNA sample that can be amplified, and

(d) correcting a diagnostic digital PCR performed on the cfDNA sample using the correction factor determined in step (c) to quantify the level of chimeric DNA.

2. The method of claim 1 , wherein step (b) further comprises an amplification reaction that targets DNA that was added to the blood, serum, or plasma sample prior to extraction.

3. The method of claim 1 , wherein the first and second amplicons differ in length by 100 nucleotides or more.

4. The method of claim 1 , wherein the longer of the first and second amplicons is from 150 to 400 base pairs in length and the shorter of the first and the second amplicons is from 50 to 150 base pairs in length.

5. The method of claim 1 , wherein the cfDNA sample is from a transplant patient.

6. The method of claim 1 , wherein the cfDNA sample is from a cancer patient.

7. The method of claim 1 , wherein the cfDNA sample is from a pregnant patient.

8. The method of claim 1 , wherein the patient is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2017
From: SCHÜTZ, EKKEHARD; BECK, JULIA
To: CHRONIX BIOMEDICAL
Reel/Frame 042883/0277 →
Continuity (2)
Provisional Application 62058261 · Oct 1, 2014
Related Publication 20170327869A1 · Nov 16, 2017
Cited By (1)
US 12,637,714